SBIR/STTR Research Award

NIH Phase II-UNCD as Bio-Inert Interface for Anti-Thrombogenicity Applications in

Award identifier 8fe0ee520c5f4a642db7f9f20c6f9c473d999e45d00f710d8fd6d0bdea6b1c33Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$192,034

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Lucidicor Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
MJJ5T4CLG1U9
Solicitation number
PA10-122
Topic code
NCI

Research abstract

DESCRIPTION: Protein kinases are chemically tractable drug targets, yet less than 5% of the human kinome has been thoroughly explored with selective small molecule inhibitors to demonstrate their therapeutic utility. Pharmaceutical companies are interested in evaluation of the therapeutic potential of targeting kinases to define new opportunities to address unmet medical needs. Lucidicor, Inc. has identified and extensively engineered an unusual marine-derived protein, termed PhosFluor , which varies itsfluorescence upon phosphorylation. We have extensively engineered native PhosFluor using Protein Kinase A as a prototype, and are developing this into a cell-based fluorescence assay that provides real-time in vivo visualization of protein phosphorylation. This platform can be applied to virtually any of the 518 protein kinases of the human kinome. The objective of this application is to optimize our novel cell-based platform to respond to protein kinase inhibitors. The working hypothesis is that PhosFluorcan easily be engineered to fluoresce in response to other protein kinases, and can therefore be used monitor the action of compounds that have been developed to modulate protein kinases. Our experimental approach will be to create additional PhosFluorderivatives by converting engineered phosphorylation sites into substrate sequences for a tyrosine kinase (Fyn kinase) and a cyclin-dependent protein kinase (cdk5). The rationale for the proposed research is that many well-characterized compounds have already been developed for these kinases, and that the successful testing of these biosensors will enable us to determine the effectiveness of our screening method. The proposed research is significant, because it is offers a novel cellular screening platformfor new drugs to target kinases and phosphatases, which may result in innovative treatments for disorders such as cancer, inflammation, pain and neuropsychiatric disorders. Finally, this new technology will be convertible to a wide array of protein kinases, greatly expanding the number of drug targets that may potentially be screened. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health because developing methods to study and screen protein kinasesis ultimately expected to facilitate the search for compounds that may be efficacious for various diseases, including inflammation, cancer, neurological disorders and metabolic conditions. Thus, the proposed research is relevant to mission of the NIH to eliminate suffering and death due to disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2011–2019). Reported award amounts total $567,019. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.